Residual γh2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness

Radiotherapy and Oncology

Volumn 116, Issue 3, 2015, Pages 480-485

  Menegakis, Apostolos ^a,b,g   De Colle, Chiara ^c   Yaromina, Ala ^d   Hennenlotter, Joerg ^a   Stenzl, Arnulf ^a   Scharpf, Marcus ^a   Fend, Falko ^a   Noell, Susan ^a   Tatagiba, Marcos ^a   Brucker, Sara ^a   Wallwiener, Diethelm ^a   Boeke, Simon ^a,b   Ricardi, Umberto ^c   Baumann, Michael ^b,e,f   Zips, Daniel ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF TURIN   (Italy)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

DNA repair; Intrinsic radiation sensitivity; Personalized radiation oncology; Radiotherapy; Tumour specimens; H2AX foci

Indexed keywords

GAMMA HISTONE H2AX; HISTONE H2AX; UNCLASSIFIED DRUG; H2AFX PROTEIN, HUMAN; HISTONE;

BLADDER CARCINOMA; BREAST CARCINOMA; CHONDROSARCOMA; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; EX VIVO STUDY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IRRADIATION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIOSENSITIVITY; SEMINOMA; SIMULATION; UTERINE CERVIX CARCINOMA; ANALYSIS OF VARIANCE; DNA REPAIR; EVALUATION STUDY; FEASIBILITY STUDY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; MALE; METABOLISM; NEOPLASMS; PROSPECTIVE STUDY; RADIATION RESPONSE; RADIATION TOLERANCE;

ANALYSIS OF VARIANCE; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEASIBILITY STUDIES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HISTONES; HUMANS; MALE; NEOPLASMS; PROSPECTIVE STUDIES; RADIATION TOLERANCE;

EID: 84944172326     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2015.08.006     Document Type: Conference Paper

References (56)

1. J.E. Bibault, I. Fumagalli, C. Ferte, C. Chargari, J.C. Soria, and E. Deutsch Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review Cancer Metastasis Rev 32 2013 479 492
2. A.H. Ree, and K.R. Redalen Personalized radiotherapy: concepts, biomarkers and trial design Br J Radiol 88 2015 20150009
3. A. Yaromina, M. Krause, and M. Baumann Individualization of cancer treatment from radiotherapy perspective Mol Oncol 6 2012 211 221
4. S.M. Bentzen, and V. Gregoire Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription Semin Radiat Oncol 21 2011 101 110
5. R. Butof, A. Dubrovska, and M. Baumann Clinical perspectives of cancer stem cell research in radiation oncology Radiother Oncol 108 2013 388 396
6. F. Lohaus, A. Linge, I. Tinhofer, V. Budach, E. Gkika, and M. Stuschke HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) Radiother Oncol 2014
7. M.H. Martens, S. Subhani, L.A. Heijnen, D.M. Lambregts, J. Buijsen, M. Maas, and et al. Can perfusion MRI predict response to preoperative treatment in rectal cancer? Radiother Oncol 114 2015 218 223
8. M.M. Nijkamp, P.N. Span, C.H. Terhaard, P.A. Doornaert, J.A. Langendijk, P.L. van den Ende, and et al. Epidermal growth factor receptor expression in laryngeal cancer predicts the effect of hypoxia modification as an additive to accelerated radiotherapy in a randomised controlled trial Eur J Cancer 49 2013 3202 3209
9. V. Valentini, R.G. van Stiphout, G. Lammering, M.A. Gambacorta, M.C. Barba, M. Bebenek, and et al. Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer Radiother Oncol 114 2015 302 309
10. M. Someya, H. Yamamoto, M. Nojima, M. Hori, K. Tateoka, K. Nakata, and et al. Relation between Ku80 and microRNA-99a expression and late rectal bleeding after radiotherapy for prostate cancer Radiother Oncol 115 2015 235 239
11. T.P. Coroller, P. Grossmann, Y. Hou, E. Rios Velazquez, R.T. Leijenaar, G. Hermann, and et al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma Radiother Oncol 114 2015 345 350
12. J. Deacon, M.J. Peckham, and G.G. Steel The radioresponsiveness of human tumours and the initial slope of the cell survival curve Radiother Oncol 2 1984 317 323
13. B. Fertil, and E.P. Malaise Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy Int J Radiat Oncol Biol Phys 7 1981 621 629
14. E.P. Malaise, B. Fertil, N. Chavaudra, and M. Guichard Distribution of radiation sensitivities for human tumor cells of specific histological types: comparison of in vitro to in vivo data Int J Radiat Oncol Biol Phys 12 1986 617 624
15. E. Dikomey, and I. Brammer Relationship between cellular radiosensitivity and non-repaired double-strand breaks studied for different growth states, dose rates and plating conditions in a normal human fibroblast line Int J Radiat Biol 76 2000 773 781
16. S. Wada, T. Van Khoa, Y. Kobayashi, T. Funayama, K. Ogihara, S. Ueno, and et al. Prediction of cellular radiosensitivity from DNA damage induced by gamma-rays and carbon ion irradiation in canine tumor cells J Vet Med Sci 67 2005 1089 1095
17. S.P. Jackson Sensing and repairing DNA double-strand breaks Carcinogenesis 23 2002 687 696
18. A. Ivashkevich, C.E. Redon, A.J. Nakamura, R.F. Martin, and O.A. Martin Use of the gamma-H2AX assay to monitor DNA damage and repair in translational cancer research Cancer Lett 327 2012 123 133
19. C.E. Redon, U. Weyemi, P.R. Parekh, D. Huang, A.S. Burrell, and W.M. Bonner Gamma-H2AX and other histone post-translational modifications in the clinic Biochim Biophys Acta 1819 2012 743 756
20. A. Sak, and M. Stuschke Use of gammaH2AX and other biomarkers of double-strand breaks during radiotherapy Semin Radiat Oncol 20 2010 223 231
21. P.L. Olive, and J.P. Banath Phosphorylation of histone H2AX as a measure of radiosensitivity Int J Radiat Oncol Biol Phys 58 2004 331 335
22. E.P. Rogakou, D.R. Pilch, A.H. Orr, V.S. Ivanova, and W.M. Bonner DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139 J Biol Chem 273 1998 5858 5868
23. W.M. Bonner, C.E. Redon, J.S. Dickey, A.J. Nakamura, O.A. Sedelnikova, S. Solier, and et al. GammaH2AX and cancer Nat Rev Cancer 8 2008 957 967
24. J.A. Downs Chromatin structure and DNA double-strand break responses in cancer progression and therapy Oncogene 26 2007 7765 7772
25. J.A. Downs, and J. Cote Dynamics of chromatin during the repair of DNA double-strand breaks Cell Cycle 4 2005 1373 1376
26. J.A. Downs, M.C. Nussenzweig, and A. Nussenzweig Chromatin dynamics and the preservation of genetic information Nature 447 2007 951 958
27. J. Fillingham, M.C. Keogh, and N.J. Krogan GammaH2AX and its role in DNA double-strand break repair Biochem Cell Biol 84 2006 568 577
28. C.R. Hunt, D. Ramnarain, N. Horikoshi, P. Iyengar, R.K. Pandita, J.W. Shay, and et al. Histone modifications and DNA double-strand break repair after exposure to ionizing radiations Radiat Res 179 2013 383 392
29. A. Kinner, W. Wu, C. Staudt, and G. Iliakis Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin Nucleic Acids Res 36 2008 5678 5694
30. R. Scully, and A. Xie Double strand break repair functions of histone H2AX Mutat Res 750 2013 5 14
31. V. Turinetto, and C. Giachino Multiple facets of histone variant H2AX: a DNA double-strand-break marker with several biological functions Nucleic Acids Res 43 2015 2489 2498
32. D. Chowdhury, M.C. Keogh, H. Ishii, C.L. Peterson, S. Buratowski, and J. Lieberman Gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair Mol Cell 20 2005 801 809
33. M. Downey, and D. Durocher GammaH2AX as a checkpoint maintenance signal Cell Cycle 5 2006 1376 1381
34. M.C. Keogh, J.A. Kim, M. Downey, J. Fillingham, D. Chowdhury, J.C. Harrison, and et al. A phosphatase complex that dephosphorylates gammaH2AX regulates DNA damage checkpoint recovery Nature 439 2006 497 501
35. S. Nakada, G.I. Chen, A.C. Gingras, and D. Durocher PP4 is a gamma H2AX phosphatase required for recovery from the DNA damage checkpoint EMBO Rep 9 2008 1019 1026
36. S.H. Moon, T.A. Nguyen, Y. Darlington, X. Lu, and L.A. Donehower Dephosphorylation of gamma-H2AX by WIP1: an important homeostatic regulatory event in DNA repair and cell cycle control Cell Cycle 9 2010 2092 2096
37. J.P. Banath, D. Klokov, S.H. MacPhail, C.A. Banuelos, and P.L. Olive Residual gammaH2AX foci as an indication of lethal DNA lesions BMC Cancer 10 2010 4
38. J.P. Banath, S.H. Macphail, and P.L. Olive Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines Cancer Res 64 2004 7144 7149
39. D. Klokov, S.M. MacPhail, J.P. Banath, J.P. Byrne, and P.L. Olive Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays Radiother Oncol 80 2006 223 229
40. A. Menegakis, A. Yaromina, W. Eicheler, A. Dorfler, B. Beuthien-Baumann, H.D. Thames, and et al. Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by gammaH2AX staining Int J Radiat Biol 85 2009 1032 1041
41. P.L. Olive Retention of gammaH2AX foci as an indication of lethal DNA damage Radiother Oncol 101 2011 18 23
42. C.A. Banuelos, J.P. Banath, J.Y. Kim, C. Aquino-Parsons, and P.L. Olive GammaH2AX expression in tumors exposed to cisplatin and fractionated irradiation Clin Cancer Res 15 2009 3344 3353
43. U. Koch, K. Hohne, C. von Neubeck, H.D. Thames, A. Yaromina, J. Dahm-Daphi, and et al. Residual gammaH2AX foci predict local tumour control after radiotherapy Radiother Oncol 108 2013 434 439
44. A. Menegakis, W. Eicheler, A. Yaromina, H.D. Thames, M. Krause, and M. Baumann Residual DNA double strand breaks in perfused but not in unperfused areas determine different radiosensitivity of tumours Radiother Oncol 100 2011 137 144
45. A. Menegakis, C. von Neubeck, A. Yaromina, H. Thames, S. Hering, and J. Hennenlotter GammaH2AX assay in ex vivo irradiated tumour specimens: a novel method to determine tumour radiation sensitivity in patient-derived material Radiother Oncol 2015
46. F.E. Bleeker, R.J. Molenaar, and S. Leenstra Recent advances in the molecular understanding of glioblastoma J Neurooncol 108 2012 11 27
47. E.B. Holliday, H.S. Mitra, J.S. Somerson, L.D. Rhines, A. Mahajan, P.D. Brown, and et al. Postoperative proton therapy for chordomas and chondrosarcomas of the spine: adjuvant versus salvage radiation therapy Spine 40 2015 544 549
48. R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J. Taphoorn, R.C. Janzer, and et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
49. D. Zips, K. Zophel, N. Abolmaali, R. Perrin, A. Abramyuk, R. Haase, and et al. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer Radiother Oncol 105 2012 21 28
50. A. Franzini, F. Baty, I.I. Macovei, O. Durr, C. Droege, and D. Betticher Gene expression signatures predictive of bevacizumab/erlotinib therapeutic benefit in advanced non-squamous non-small cell lung cancer patients (SAKK 19/05 trial) Clin Cancer Res 2015
51. K.A. Naipal, N.S. Verkaik, N. Ameziane, C.H. van Deurzen, P. Ter Brugge, M. Meijers, and et al. Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment Clin Cancer Res 20 2014 4816 4826
52. M.M. Shah, Z.C. Dobbin, S. Nowsheen, M. Wielgos, A.A. Katre, R.D. Alvarez, and et al. An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer Gynecol Oncol 134 2014 331 337
53. C.M. West, S.E. Davidson, P.A. Burt, and R.D. Hunter The intrinsic radiosensitivity of cervical carcinoma: correlations with clinical data Int J Radiat Oncol Biol Phys 31 1995 841 846
54. C.M. West, S.E. Davidson, S.A. Roberts, and R.D. Hunter The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix Br J Cancer 76 1997 1184 1190
55. K. Rothkamm, S. Barnard, E.A. Ainsbury, J. Al-Hafidh, J.F. Barquinero, C. Lindholm, and et al. Manual versus automated gamma-H2AX foci analysis across five European laboratories: can this assay be used for rapid biodosimetry in a large scale radiation accident? Mutat Res 756 2013 170 173
56. R. Runge, R. Hiemann, M. Wendisch, U. Kasten-Pisula, K. Storch, K. Zophel, and et al. Fully automated interpretation of ionizing radiation-induced gammaH2AX foci by the novel pattern recognition system AKLIDES(R) Int J Radiat Biol 88 2012 439 447